Data gathered: February 8
Alternative Data for Royalty Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,310 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 98 | Sign up | Sign up | Sign up |
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
| Price | $31.73 |
| Target Price | Sign up |
| Volume | 3,160,000 |
| Market Cap | $18.5B |
| Year Range | $24.28 - $31.95 |
| Dividend Yield | 2.8% |
| PE Ratio | 12.36 |
| Analyst Rating | 100% buy |
| Earnings Date | February 11 '25 |
| Industry | Biotechnology |
In the news
 |
Fifth Third Bancorp Buys 997 Shares of Royalty Pharma plc (NASDAQ:RPRX)February 3 - ETF Daily News |
Royalty Pharma Announces Sale of MorphoSys Development Funding BondsJanuary 28 - Finnhub |
|
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025January 28 - Finnhub |
|
|
Ballentine Partners LLC Acquires Shares of 7,846 Royalty Pharma plc (NASDAQ:RPRX)January 26 - ETF Daily News |
Royalty Pharma : Q4 2024 Pre-Quarterly CommunicationJanuary 24 - Finnhub |
|
|
Traders Purchase High Volume of Call Options on Royalty Pharma (NASDAQ:RPRX)January 15 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 565M | -171M | 736M | 544M | 873M | 1.010 |
| Q2 '24 | 537M | 267M | 270M | 102M | 560M | 0.960 |
| Q1 '24 | 568M | 642M | -74M | 4.8M | 40M | 0.980 |
| Q4 '23 | 596M | -26M | 623M | 494M | 674M | 1.150 |
| Q3 '23 | 536M | 334M | 202M | 72M | 168M | 0.790 |
Insider Transactions View All
| RIGGS RORY B filed to sell 20,099 shares at $27.5. January 4 '24 |
| RIGGS RORY B filed to sell 55,801 shares at $27.8. January 4 '24 |
| RIGGS RORY B filed to sell 254,899 shares at $28.5. January 4 '24 |
| Giuliani Mario Germano filed to sell 2,477,520 shares at $28. January 3 '24 |
| Giuliani Mario Germano filed to sell 2,543,323 shares at $28.2. December 29 '23 |
Similar companies
Read more about Royalty Pharma (RPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Royalty Pharma?
The Market Cap of Royalty Pharma is $18.5B.
What is Royalty Pharma's PE Ratio?
As of today, Royalty Pharma's PE (Price to Earnings) ratio is 12.36.
When does Royalty Pharma report earnings?
Royalty Pharma will report its next earnings on February 11 '25.
What is the current stock price of Royalty Pharma?
Currently, the price of one share of Royalty Pharma stock is $31.73.
How can I analyze the RPRX stock price chart for investment decisions?
The RPRX stock price chart above provides a comprehensive visual representation of Royalty Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Royalty Pharma shares. Our platform offers an up-to-date RPRX stock price chart, along with technical data analysis and alternative data insights.
Does RPRX offer dividends to its shareholders?
Yes, Royalty Pharma (RPRX) offers dividends to its shareholders, with a dividend yield of 2.8%. This dividend yield represents Royalty Pharma's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Royalty Pharma in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Royalty Pharma?
Some of the similar stocks of Royalty Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.